Psychopharmacological comparison of schizophrenia spectrum disorder with and without cannabis dependency

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 1, 2011, Pages 212-217

  Makkos, Zoltan ^a   Fejes, Lilla ^a   Inczédy Farkas, Gabriella ^b   Kassai Farkas, Akos ^a   Faludi, Gabor ^b   Lazary, Judit ^b  

^a Nyírö Gyula Hospital   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Addiction; Cannabis; Psychopharmacotherapy; Psychosis; THC

Indexed keywords

ALPRAZOLAM; ARIPIPRAZOLE; CLONAZEPAM; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; CANNABIS ADDICTION; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HOSPITALIZATION; HUMAN; INTERVIEW; LENGTH OF STAY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PSYCHOLOGIC ASSESSMENT; SCHIZOPHRENIA; SEX DIFFERENCE; SHORT COURSE THERAPY; SMOKING; SUICIDE ATTEMPT; TREATMENT DURATION;

ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MENTAL RECALL; ODDS RATIO; PREVALENCE; PSYCHOPHARMACOLOGY; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; SEX FACTORS; SUICIDE, ATTEMPTED; TIME FACTORS; YOUNG ADULT;

EID: 78650944917     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.11.007     Document Type: Article

References (66)

1. Andreasson S., Allebeck P., Engstrom A., Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987, 2:1483-1486.
2. Arendt M., Rosenberg R., Foldager L., Perto G., Munk-Jorgensen P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry 2005, 187:510-515.
3. Arendt M., Mortensen P.B., Rosenberg R., Pedersen C.B., Waltoft B.L. Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia. Arch Gen Psychiatry 2008, 65:1269-1274.
4. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., Moffitt T.E. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Bmj 2002, 325:1212-1213.
5. Auquier P., Lancon C., Rouillon F., Lader M. Mortality in schizophrenia. Pharmacoepidemiol Drug Saf 2007, 16:1308-1312.
6. Barnes T.R., Mutsatsa S.H., Hutton S.B., Watt H.C., Joyce E.M. Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry 2006, 188:237-242.
7. Barrigon M.L., Gurpegui M., Ruiz-Veguilla M., Diaz F.J., Anguita M., Sarramea F., et al. Temporal relationship of first-episode non-affective psychosis with cannabis use: a clinical verification of an epidemiological hypothesis. J Psychiatr Res 2010, 44:413-420.
8. Basu D., Malhotra A., Bhagat A., Varma V.K. Cannabis psychosis and acute schizophrenia. A case-control study from India. Eur Addict Res 1999, 5:71-73.
9. Bersani G., Orlandi V., Kotzalidis G.D., Pancheri P. Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci 2002, 252:86-92.
10. Boydell J., van Os J., Caspi A., Kennedy N., Giouroukou E., Fearon P., et al. Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999. Psychol Med 2006, 36:1441-1446.
11. Boydell J., Dean K., Dutta R., Giouroukou E., Fearon P., Murray R. A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: implications for the concept of cannabis psychosis. Schizophr Res 2007, 93:203-210.
12. Buhler B., Hambrecht M., Loffler W., an der Heiden W., Hafner H. Precipitation and determination of the onset and course of schizophrenia by substance abuse-a retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res 2002, 54:243-251.
13. Chaudry H.R., Moss H.B., Bashir A., Suliman T. Cannabis psychosis following bhang ingestion. Br J Addict 1991, 86:1075-1081.
14. Chavarria-Siles I., Contreras-Rojas J., Hare E., Walss-Bass C., Quezada P., Dassori A., et al. Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2008, 147:279-284.
15. Cheng M.C., Liao D.L., Hsiung C.A., Chen C.Y., Liao Y.C., Chen C.H. Chronic treatment with aripiprazole induces differential gene expression in the rat frontal cortex. Int J Neuropsychopharmacol 2008, 11:207-216.
16. Compton M.T., Kelley M.E., Ramsay C.E., Pringle M., Goulding S.M., Esterberg M.L., et al. Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. Am J Psychiatry 2009, 166:1251-1257.
17. Corcoran C.M., Kimhy D., Stanford A., Khan S., Walsh J., Thompson J., et al. Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis. Schizophr Res 2008, 106:286-293.
18. De Marchi N., De Petrocellis L., Orlando P., Daniele F., Fezza F., Di Marzo V. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis 2003, 2:5.
19. Degenhardt L., Tennant C., Gilmour S., Schofield D., Nash L., Hall W., et al. The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychol Med 2007, 37:927-934.
20. Drake R.E., Xie H., McHugo G.J., Green A.I. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000, 26:441-449.
21. D'Souza D.C., Sewell R.A., Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci 2009, 259:413-431.
22. Fernandez-Espejo E., Viveros M.P., Nunez L., Ellenbroek B.A., Rodriguez de Fonseca F. Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology (Berl) 2009, 206:531-549.
23. Giuffrida A., Leweke F.M., Gerth C.W., Schreiber D., Koethe D., Faulhaber J., et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004, 29:2108-2114.
24. Gonzalez-Pinto A., Vega P., Ibanez B., Mosquera F., Barbeito S., Gutierrez M., et al. Impact of cannabis and other drugs on age at onset of psychosis. J Clin Psychiatry 2008, 69:1210-1216.
25. Green B., Young R., Kavanagh D. Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry 2005, 187:306-313.
26. Hamdani N., Tabeze J.P., Ramoz N., Ades J., Hamon M., Sarfati Y., et al. The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia. Eur Neuropsychopharmacol 2008, 18:34-40.
27. Hart C.L., van Gorp W., Haney M., Foltin R.W., Fischman M.W. Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology 2001, 25:757-765.
28. Heishman S.J., Huestis M.A., Henningfield J.E., Cone E.J. Acute and residual effects of marijuana: profiles of plasma THC levels, physiological, subjective, and performance measures. Pharmacol Biochem Behav 1990, 37:561-565.
29. Henquet C., Murray R., Linszen D., van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr Bull 2005, 31:608-612.
30. Hooker W.D., Jones R.T. Increased susceptibility to memory intrusions and the Stroop interference effect during acute marijuana intoxication. Psychopharmacology (Berl) 1987, 91:20-24.
31. Keshavan M.S., Anderson S., Pettegrew J.W. Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited. J Psychiatr Res 1994, 28:239-265.
32. Kristensen K., Cadenhead K.S. Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res 2007, 151:151-154.
33. Leung A., Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl 2000, 401:3-38.
34. Leweke M., Kampmann C., Radwan M., Dietrich D.E., Johannes S., Emrich H.M., et al. The effects of tetrahydrocannabinol on the recognition of emotionally charged words: an analysis using event-related brain potentials. Neuropsychobiology 1998, 37:104-111.
35. Leweke F.M., Giuffrida A., Wurster U., Emrich H.M., Piomelli D. Elevated endogenous cannabinoids in schizophrenia. NeuroReport 1999, 10:1665-1669.
36. Linszen D.H., Dingemans P.M., Lenior M.E. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994, 51:273-279.
37. Marks D.F., MacAvoy M.G. Divided attention performance in cannabis users and non-users following alcohol and cannabis separately and in combination. Psychopharmacology (Berl) 1989, 99:397-401.
38. Mathers D.C., Ghodse A.H. Cannabis and psychotic illness. Br J Psychiatry 1992, 161:648-653.
39. Mauri M.C., Volonteri L.S., De Gaspari I.F., Colasanti A., Brambilla M.A., Cerruti L. Substance abuse in first-episode schizophrenic patients: a retrospective study. Clin Pract Epidemiol Mental Health 2006, 2:4.
40. McGuire P.K., Jones P., Harvey I., Williams M., McGuffin P., Murray R.M. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr Res 1995, 15:277-281.
41. Miller L.L., McFarland D., Cornett T.L., Brightwell D. Marijuana and memory impairment: effect on free recall and recognition memory. Pharmacol Biochem Behav 1977, 7:99-103.
42. Miller P., Lawrie S.M., Hodges A., Clafferty R., Cosway R., Johnstone E.C. Genetic liability, illicit drug use, life stress and psychotic symptoms: preliminary findings from the Edinburgh study of people at high risk for schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2001, 36:338-342.
43. Miller R., Ream G., McCormack J., Gunduz-Bruce H., Sevy S., Robinson D. A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia. Schizophr Res 2009, 113:138-144.
44. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
45. Mueser K.T., McGurk S.R. Schizophrenia. Lancet 2004, 363:2063-2072.
46. Nunez L.A., Gurpegui M. Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia. Acta Psychiatr Scand 2002, 105:173-178.
47. Pertwee R.G. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J 2005, 7:E625-E654.
48. Potvin S., Stip E., Lipp O., Elie R., Mancini-Marie A., Demers M.F., et al. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Curr Med Res Opin 2006, 22:1277-1285.
49. Rabinowitz J., Bromet E.J., Lavelle J., Carlson G., Kovasznay B., Schwartz J.E. Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychol Med 1998, 28:1411-1419.
50. Ranganathan M., D'Souza D.C. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl) 2006, 188:425-444.
51. Robbe D., Alonso G., Duchamp F., Bockaert J., Manzoni O.J. Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. J Neurosci 2001, 21:109-116.
52. Rolfe M., Tang C.M., Sabally S., Todd J.E., Sam E.B., Hatib N'Jie A.B. Psychosis and cannabis abuse in The Gambia. A case-control study. Br J Psychiatry 1993, 163:798-801.
53. Ruiz-Veguilla M., Gurpegui M., Barrigon M.L., Ferrin M., Marin E., Rubio J.L., et al. Fewer neurological soft signs among first episode psychosis patients with heavy cannabis use. Schizophr Res 2009, 107:158-164.
54. Schiffman J., Nakamura B., Earleywine M., LaBrie J. Symptoms of schizotypy precede cannabis use. Psychiatry Res 2005, 134:37-42.
55. Schmidt L.G., Samochowiec J., Finckh U., Fiszer-Piosik E., Horodnicki J., Wendel B., et al. Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug Alcohol Depend 2002, 65:221-224.
56. Silver H., Abboud E. Drug abuse in schizophrenia: comparison of patients who began drug abuse before their first admission with those who began abusing drugs after their first admission. Schizophr Res 1994, 13:57-63.
57. Soyka M. Substance misuse, psychiatric disorder and violent and disturbed behaviour. Br J Psychiatry 2000, 176:345-350.
58. Soyka M., Albus M., Immler B., Kathmann N., Hippius H. Psychopathology in dual diagnosis and non-addicted schizophrenics-are there differences?. Eur Arch Psychiatry Clin Neurosci 2001, 251:232-238.
59. Sugranyes G., Flamarique I., Parellada E., Baeza I., Goti J., Fernandez-Egea E., et al. Cannabis use and age of diagnosis of schizophrenia. Eur Psychiatry 2009, 24:282-286.
60. Sundram S., Copolov D., Dean B. Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn Schmiedebergs Arch Pharmacol 2005, 371:428-433.
61. Ujike H. Stimulant-induced psychosis and schizophrenia: the role of sensitization. Curr Psychiatry Rep 2002, 4:177-184.
62. van Os J., Bak M., Hanssen M., Bijl R.V., de Graaf R., Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002, 156:319-327.
63. Veen N.D., Selten J.P., van der Tweel I., Feller W.G., Hoek H.W., Kahn R.S. Cannabis use and age at onset of schizophrenia. Am J Psychiatry 2004, 161:501-506.
64. Wiley J.L., Kendler S.H., Burston J.J., Howard D.R., Selley D.E., Sim-Selley L.J. Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivo pharmacology in rats. Neuropharmacology 2008, 55:1183-1190.
65. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003, 64:663-667.
66. Zimmet S.V., Strous R.D., Burgess E.S., Kohnstamm S., Green A.I. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol 2000, 20:94-98.